Dr Goss talks to ecancer at ESMO 2024 about data he presented from the Canadian Cancer Trials Group BR.31 study.

The trial tested whether there was a benefit to receiving adjuvant durvalumab after complete tumour resection and optional chemotherapy in early-stage (IB-IIIA) non-small cell lung cancer.

The study did not meet its primary endpoint which was targeting a significant improvement in disease free survival in NSCLC patients whose tumours had a tumour cell PD-L1 score of 25% or greater and were EGFR/ALK wildtype.